KASMEJ
Kastamonu Medical Journal

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

ISSN: Passive
eISSN: 2757-9336
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Overlooked challenges after kidney transplantation: non-immunologic complications from a single-center experience
Abstract
Aims: This study investigates non-immunologic complications in kidney transplant recipients, focusing on their incidence and risk factors.
Methods: A retrospective observational analysis was conducted on 416 adult patients who underwent kidney transplantation at a tertiary care hospital between 2002 and 2016. Demographic, clinical, and laboratory data, as well as post-transplant complications, were extracted from medical records. Statistical analysis was performed to evaluate risk factors associated with new-onset diabetes mellitus (NODAT), hypertension, dyslipidemia, hyperuricemia, and avascular necrosis.
Results: The most common complication was dyslipidemia (70.2%), followed by NODAT (24.8%), hypertension (19.7%), hyperuricemia (10.6%), and avascular necrosis (4.8%). Advanced age, higher BMI, elevated CRP, male gender, and CMV positivity were significantly associated with NODAT. Hypertension was linked to calcineurin inhibitor use, while dyslipidemia correlated with higher BMI and cyclosporine therapy. Hyperuricemia was significantly associated with lower GFR and male gender. Avascular necrosis was predominantly observed in glucocorticoid-treated patients. Effective management of these complications is critical to improving patient outcomes.
Conclusion: Metabolic complications are prevalent and have a significant impact on post-transplant survival. Regular follow-up and individualized management strategies are essential to address these risks and enhance long-term outcomes for kidney transplant recipients. Further multicenter prospective studies are recommended to validate these findings.

Keywords : Kidney transplantation, postoperative complications, non-immunologic complications, new-onset diabetes after transplantation (NODAT), metabolic diseases

Download Article


1. Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):5-14.
2. Bottomley MJ, Harden PN. Update on the long-term complications of renal transplantation. Br Med Bull. 2013;106:117-134. doi:10.1093/bmb/ldt012
3. Braun WE. Long-term complications of renal transplantation. Kidney Int. 1990;37(5):1363-1378. doi:10.1038/ki.1990.123
4. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant. 1999;14(3): 648-54. doi:10.1093/ndt/14.3.648
5. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82(5):603-611. doi:10.1097/01.tp.0000235527.81917.fe
6. Scherer MN, Banas B, Mantouvalou K, et al. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg. 2007;392(5):511-523. doi:10.1007/s00423-007-0188-z
7. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation. 2005;80(2 Suppl): S221-S234. doi:10.1097/01.tp.0000186386.13597.cb
8. Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes. 2011;4:175-186. doi:10.2147/DMSO.S19027
9. Thomas B, Taber DJ, Srinivas TR. Hypertension after kidney transplantation: a pathophysiologic approach. Curr Hypertens Rep. 2013;15(5):458-69. doi:10.1007/s11906-013-0381-0
10. Ramezani M, Einollahi B, Ahmadzad-Asl M, et al. Hyperlipidemia after renal transplantation and its relation to graft and patient survival. Transplant Proc. 2007;39(4):1044-1047. doi:10.1016/j.transproceed.2007. 03.035
11. Laures AS, Gomez E, Baltar J, Alvarez-Grande J. Risk factors for cardiovascular disease during the first 2 years after renal transplantation. Transplant Proc. 2005;37(9):3778-3781. doi:10.1016/j.transproceed.2005. 09.201
12. Karakan Ş, Sezer S, Acar Ö, Nurhan F. Böbrek nakli sonrası yeni diyabetes mellitus gelişmesine etki eden faktörler; obezite ve inflamasyonun rolü. Fırat Tıp Dergisi. 2013;18(2):122-125.
13. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis. 2004; 43(6):953-965. doi:10.1053/j.ajkd.2004.03.020
14. Hornum M, Lindahl JP, von Zur-Muhlen B, Jenssen T, Feldt-Rasmussen B. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies. Transpl Int. 2013;26(11):1049-1060. doi:10.1111/tri.12112
15. Weir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015;26(6):1248-1260. doi:10.1681/ASN.2014080834
16. Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm. 2004;61(6):565-585. doi:10.1093/ajhp/61.6.565
17. You L, Liu A, Wuyun G, Wu H, Wang P. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area. J Atheroscler Thromb. 2014;21(4):355-365. doi:10.5551/jat.20529
18. Eckardt KU, Kasiske BL, Zeier MG. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9:S1-S155. doi:10.1111/j.1600-6143.2009.02834.x
19. Reddi V, First M. Medical complication of kidney transplantation. 2000: 608.
20. Süleymanlar G, Serdengeçti K, Erek E. Türkiye’de son dönem böbrek yetmezliğinin epidemiyolojisi. Turk Clinc J Int Med Sci. 2005;1(21):1-8.
21. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2): 178-185. doi:10.1034/j.1600-6143.2003.00010.x
22. Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S38-S48. doi:10.2215/CJN.02650707
23. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines1. Transplantation. 2003;75(10):SS3-SS24. doi:10.1097/01.TP.0000069952. 49242.3E
24. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59(2):732-737. doi:10.1046/j.1523-1755.2001.059002732.x
25. Tobin G, Klein C, Brennan D. New onset diabetes after transplantation in renal transplant recipients. UPTODATE. 2012.
26. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69(3):588-595. doi:10.1038/sj.ki.5000116
27. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41(10):1241-1248. doi:10.1007/s00 1250051058
28. Edition T. The prevention and management of CMV disease after solid organ transplantation. 2015.
29. Hjelmesaeth J, Muller F, Jenssen T, Rollag H, Sagedal S, Hartmann A. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant. 2005;20(11):2311-2315. doi:10.1093/ndt/gfi033
30. Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era-an analysis of risk factors. Transplantation. 1991;51(2):343-347. doi:10.1097/00007890-199102000-00014
31. Yu H, Kim H, Baek CH, et al. Risk factors for new-onset diabetes mellitus after living donor kidney transplantation in Korea-a retrospective single center study. BMC Nephrol. 2016;17(1):106. doi:10.1186/s12882-016-0321-8
32. Tedla F, Hayashi R, McFarlane SI, Salifu MO. Hypertension after renal transplant. J Clin Hypertens (Greenwich). 2007;9(7):538-545. doi:10.1111/j.1524-6175.2007.06588.x
33. Barbari A. Posttransplant hypertension: multipathogenic disease process. Exp Clin Transplant. 2013;11(2):99-108. doi:10.6002/ect.2012. 0311
34. Opelz G, Dohler B, Collaborative Transplant S. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation. 2009;87(6):795-802. doi: 10.1097/TP.0b013e318199c1c7
35. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol. 1994;4(Suppl 8):S30-S36. doi:10.1681/ASN.V48s30
36. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11(9):1735-1743. doi:10.1681/ASN.V1191735
37. Thomas B, Taber DJ, Srinivas TR. Hypertension after kidney transplantation: a pathophysiologic approach. Curr Hypertens Rep. 2013;15(5):458-469. doi:10.1007/s11906-013-0381-0
38. Bastani B, Robinson S, Heisler T, et al. Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy. Clin Transplant. 1995;9(4):340-348. doi:10.1111/j.1399-0012.1995.tb00 347.x
39. Castillo RF, Garcia Rios MD, Pena Amaro P, Garcia Garcia I. Progression of alterations in lipid metabolism in kidney transplant recipients over 5 years of follow-up. Int J Clin Pract. 2014;68(9):1141-1146. doi:10.1111/ijcp.12465
40. Le N. Relationship of diet quality and weight gain post-renal transplantation. Texas Woman’s University; 2019.
41. Bellos I, Lagiou P, Benetou V, Marinaki S. Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis. Lipids Health Dis. 2024;23(1):293. doi:10.1186/s12944-024-02276-w
42. Chung BH, Kang SH, Hwang HS, et al. Clinical significance of early-onset hyperuricemia in renal transplant recipients. Nephron Clin Pract. 2011;117(3):c276-c283. doi:10.1159/000320743
43. Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol. 2009;103(6):867-871. doi:10.1016/j.amjcard.2008.11.042
44. Eyupoglu S, Eyupoglu D, Kendi-Celebi Z, et al. Risk factors of hyperuricemia after renal transplantation and its long-term effects on graft functions. Elsevier; 2017:505-508.
45. Malheiro J, Almeida M, Fonseca I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. Elsevier; 2012:2369-2372.
46. Nixon JE. Early diagnosis and treatment of steroid induced avascular necrosis of bone. Br Med J (Clin Res Ed). 1984;288(6419):741-744. doi:10. 1136/bmj.288.6419.741
47. Patton PR, Pfaff WW. Aseptic bone necrosis after renal transplantation. Surgery. 1988;103(1):63-68. </ol> <p>
Article available in :
Volume 5, Issue 3, 2025
Page : 150-156
https://doi.org/10.51271/KMJ-0201
Article Information
Received : 14 Ara 2024
Accepted : 16 Oca 2025
Published : 03 Eyl 2025
Corresponding Author :

Betül Gülsüm Yavuz Veizi: Division of Geriatrics, Department of Internal Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkiye

[email protected]
Citation : Yavuz Veizi BG, Kumru G, Erdoğmuş Ş, Tüzüner A, Keven K. Overlooked challenges after kidney transplantation: non-immunologic complications from a single-center experience. Kastamonu Med J. 2025;5(3):150-156.

Read: 234
Download : 676
Cited: 0
_Footer